NCT02929290 - Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BPI-9016M

"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."

Trial Locations (7)

100021

RECRUITING

Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing

100032

RECRUITING

Peking Union Medical College Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

110001

RECRUITING

The First Hospital of China Medical University, Shenyang

150081

NOT_YET_RECRUITING

Affiliated Cancer Hospital of Harbin Medical University, Harbin

230601

RECRUITING

The Second Affiliated Hospital of Anhui Medical University, Hefei

050011

NOT_YET_RECRUITING

Fourth Hospital of Hebei Medical University, Shijiazhuang